Telehealth has evolved from a pandemic-era necessity into a healthcare revolution. With everything from mental health counseling to prescription weight-loss drugs now just a click away, telemedicine stocks are rewriting the future of medicine. As demand for remote care surges and technology enables more personalized treatment, these five telehealth stocks stand at the forefront of innovation—and investment opportunity.
Below, we break down the top five publicly traded telehealth stocks investors should watch in 2025.
📈 1. Teladoc Health (TDOC)
Ticker: TDOC
Sector Leader | Focus: Virtual Primary Care, Chronic Conditions, Mental Health
Teladoc Health remains the undisputed heavyweight in telehealth. The company offers a comprehensive suite of services—from general virtual visits to chronic condition management and mental health therapy. Its acquisitions of Livongo and BetterHelp have expanded its footprint into long-term care and wellness.
Despite seeing its stock retreat from pandemic highs, Teladoc is steadily rebuilding investor confidence. In 2024, it brought in over $2.6 billion in revenue, showing strong demand even amid sector volatility. In 2025, Teladoc is focused on streamlining operations and pushing toward profitability, which could spark a stock turnaround.
✅ Why it matters: As healthcare systems seek efficiency and scalability, Teladoc is already integrated into hospitals, insurers, and employer plans around the globe.
💻 2. American Well (Amwell)
Ticker: AMWL
The Platform Builder | Focus: Health System Integration, Virtual Care Infrastructure
Unlike DTC players, Amwell focuses on building virtual care platforms for hospital systems, payers, and employers. It powers the telehealth portals for some of the largest healthcare institutions in the U.S.
While AMWL’s share price has dipped in recent years, its strategic partnerships and institutional reach give it long-term upside. In 2025, Amwell is expanding its suite of AI-driven care tools and investing in virtual behavioral health—a fast-growing category.
✅ Why it matters: Amwell’s white-labeled, B2B model means steady enterprise contracts and institutional buy-in.
💊 3. Hims & Hers Health (HIMS)
Ticker: HIMS
Consumer Disruptor | Focus: Wellness, Mental Health, GLP-1 Weight Loss
Hims & Hers has cracked the code on making telehealth mainstream and consumer-friendly. The company offers subscription-based services for sexual health, mental wellness, hair loss, and—most notably—weight loss medications like GLP-1s (e.g. Wegovy and Zepbound).
In Q1 2025, the company posted 111% YoY revenue growth and nearly tripled its earnings. With more than 2.4 million subscribers, HIMS is monetizing healthcare in a way that’s as easy as ordering coffee online.
That said, regulatory risks loom. HIMS recently ended a partnership with Novo Nordisk amid scrutiny over compounded versions of GLP-1 drugs. But with high brand trust and diversified offerings, the company is well-positioned to adapt.
✅ Why it matters: HIMS offers growth in one of the most explosive areas of healthcare—convenient, lifestyle-driven medicine.
⚕️ 4. LifeMD (LFMD)
Ticker: LFMD
High-Growth Underdog | Focus: GLP-1 Medications, Hormonal Therapy, Men’s Health
LifeMD might not have the brand name of Teladoc or HIMS, but it’s one of the fastest-growing telehealth stocks under the radar. The company offers online medical consultations, prescription weight-loss medications, and chronic condition care, all delivered through its tech platform.
In 2025, LifeMD expanded into women’s health and wellness, adding new customer verticals and widening its subscription base. The stock recently popped after signing pharmacy fulfillment deals for brand-name GLP-1 drugs.
With 49% revenue growth in its most recent quarter and ambitious plans to scale, LFMD is a speculative but potentially high-reward pick.
✅ Why it matters: LifeMD is a nimble innovator with strong recurring revenue and pharma partnerships.
👨⚕️ 5. Doximity (DOCS)
Ticker: DOCS
The Physician’s Network | Focus: Medical Professionals, HIPAA-Compliant Telehealth
Think of Doximity as the “LinkedIn for doctors”—but with the added bonus of built-in HIPAA-compliant video visits and secure messaging. Over 80% of U.S. physicians use Doximity to communicate, share clinical research, and consult with patients.
Unlike most telehealth firms, Doximity is profitable and still growing. Its Q3 2024 earnings showed 17% revenue growth with expanding operating margins. DOCS also benefits from its unique ad model: pharma companies pay to reach highly targeted clinician audiences.
✅ Why it matters: Doximity blends professional networking with healthcare tech in a way no other company does.
Sector Outlook for 2025
Telehealth isn’t just a pandemic trend—it’s part of a permanent transformation in healthcare delivery. Regulatory momentum, consumer comfort, and advances in AI/remote diagnostics are creating a long-term runway.
Challenges remain, especially around regulation of online prescribing and drug safety. But for investors, the rewards could be significant, particularly in companies with strong brand equity, B2B contracts, or physician networks.
📊 Final Take: Telehealth Stocks at a Glance
| Stock | Strength | 2025 Highlight |
|---|---|---|
| TDOC | Largest platform | Working toward profitability |
| AMWL | Health system integration | Building AI-enhanced care tools |
| HIMS | Consumer growth | 111% YoY revenue growth |
| LFMD | Undervalued growth play | 49% quarterly revenue jump |
| DOCS | Physician network | Profitable + strong B2B model |
📢 Want More?
Stay tuned for upcoming coverage of telehealth ETFs, AI healthcare stocks, and regulation-proof small caps. If you want this blog turned into a downloadable PDF or cross-posted to LinkedIn or Facebook, just say the word!
Be the first to comment